비교리스트

 카트 문의
시장보고서
상품코드
1490326

세계의 유전자 편집 기술 시장(2024-2034년)

Genome Editing Technologies Market Report 2024-2034
발행일: | 리서치사: Visiongain | 페이지 정보: 영문 311 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 유전자 편집 기술 시장 규모는 2034년까지 17.6%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

산업 성장을 가속하는 신흥 경제국 :

중국, 인도, 남아프리카공화국, 멕시코, 싱가포르, 브라질, 러시아, 한국, 인도네시아, 터키 등 신흥국은 유전자 편집 기술 산업에서 중요한 국가로 부상하고 있습니다. 특히 중국은 유전자 편집에 대한 대규모 투자를 통해 세계 연구 및 응용의 선두에 서고 있으며, BGI Genomics 및 Huada Genomics Institute와 같은 기관은 CRISPR-Cas9 기술을 선도하여 인간 건강 및 농업 분야에서 획기적인 발전을 이루었습니다. 하고 있습니다. 이러한 발전은 식량 안보와 지속가능성과 같은 중요한 문제를 해결하고, 중국 시장에서 생명과학 연구의 장기적인 성장 기회를 제공합니다. 중국의 R&D 비용은 2023년 4,585억 달러로 전년 대비 8.1% 증가했으며, 이는 고령화로 인한 건강 수요 증가를 반영하고 있습니다.

인도와 브라질도 유전자 편집 기술에서 괄목할 만한 진전을 이루고 있습니다. 인구가 많고 생명공학 분야가 급성장하고 있는 인도에서는 Rasi Seeds와 MedGenome과 같은 기업이 작물 개량과 개인 맞춤형 의료 연구를 주도하고 있습니다. 이러한 의료와 농업에 대한 집중은 사회적 이익을 위해 유전체 편집을 활용하겠다는 인도의 의지를 분명히 보여주고 있습니다. 브라질 역시 의료 및 농업 문제를 해결하기 위한 유전자 편집의 잠재력을 인식하고 있으며, Embrapa와 같은 기관과 Recepta Biopharma와 같은 기업들은 국가적 필요에 맞는 새로운 치료법과 작물 품종을 적극적으로 개발하여 정밀의료와 농업 생산성 향상을 추진하고 있습니다. 추진하고 있습니다. 이러한 노력으로 브라질은 전 세계 유전자 편집 분야에서 중요한 위치를 차지하고 있습니다.

세계 유전자 편집 기술(Genome Editing Technology) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
  • COVID-19의 영향 분석
  • Porter의 Five Forces 분석
  • PEST 분석

제4장 유전자 편집 기술 시장 분석 : 기술별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • CRISPR
  • TALEN
  • ZFN
  • Meganucleases
  • 기타
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제5장 유전자 편집 기술 시장 분석 : 용도별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 유전자 엔지니어링
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별
    • 세포주 엔지니어링
    • 동물 유전자 엔지니어링
    • 식물 유전자 엔지니어링
    • 기타
  • Drug Discovery & Development
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별
  • 진단
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제6장 유전자 편집 기술 시장 분석 : 최종사용자별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 바이오테크놀러지 기업
  • 제약회사
  • 학술 및 정부 연구기관
  • 기타
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제7장 유전자 편집 기술 시장 분석 : 지역별

  • 주요 조사 결과
  • 시장 규모 추이와 예측

제8장 북미의 유전자 편집 기술 시장 분석

제9장 유럽의 유전자 편집 기술 시장 분석

제10장 아시아의 유전자 편집 기술 시장 분석

제11장 라틴아메리카의 유전자 편집 기술 시장 분석

제12장 중동 및 아프리카의 유전자 편집 기술 시장 분석

제13장 기업 개요

  • 경쟁 구도
  • 전략적 전망
  • Thermo Fisher Scientific Inc.
  • Lonza
  • CRISPR Therapeutics
  • Editas Medicine
  • Revvity
  • Agilent Technologies
  • GenScript
  • Merck KGaA
  • Sangamo Therapeutics
  • Precision Biosciences
  • Tecan Trading AG
  • Takara Bio Inc.
  • Danaher Corporation
  • Recombinetics
  • Intellia Therapeutics Inc.
  • Cellectis
  • Cibus Inc.
  • Caribou Biosciences, Inc.

제14장 결론 및 제안

  • Visiongain의 결론
  • 시장 진출기업에 대한 제안
LSH 24.06.14

The global Genome Editing Technologies market is projected to grow at a CAGR of 17.6% by 2034

The Genome Editing Technologies Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Emerging Economies Projected to Boost Industry Growth

Emerging economies such as China, India, South Africa, Mexico, Singapore, Brazil, Russia, South Korea, Indonesia, and Turkey are becoming significant players in the genome editing technologies industry. China, in particular, has made substantial investments and advancements in genome editing, propelling the nation to the forefront of global research and application. Institutions like BGI Genomics and Huada Genomics Institute are leading efforts in CRISPR-Cas9 technology, achieving breakthroughs in human health and significant strides in agriculture. These advancements address critical issues such as food security and sustainability, presenting a significant long-term growth opportunity for life science research in the Chinese market. The country's spending on R&D surpassed US$458.5 billion in 2023, an 8.1% increase from the previous year, reflecting rising health demands from an aging population.

India and Brazil are also making notable progress in genome editing technologies. India, with its vast population and burgeoning biotechnology sector, has companies like Rasi Seeds and MedGenome spearheading research in crop improvement and personalized medicine. This focus on healthcare and agriculture highlights India's commitment to leveraging genome editing for societal benefit. Similarly, Brazil is recognizing the potential of genome editing to address its healthcare and agricultural challenges. Institutions like Embrapa and companies like Recepta Biopharma are actively developing novel therapies and crop varieties tailored to the country's needs, driving advancements in precision medicine and agricultural productivity. These efforts position Brazil as a key player in the global genome editing landscape.

Off-target Effects of CRISPR Technology Likely to Challenge Industry Growth

One major limitation of gene editing technology is the off-target effects of CRISPR-Cas9. While CRISPR can target specific genes with high precision, it can also cause unintended alterations at other sites in the genome. These off-target effects present risks and challenges, making it essential to ensure precise targeting to avoid unwanted changes and adverse outcomes. Researchers are improving CRISPR procedures to increase specificity and reduce off-target effects through advancements in guide RNA design, high-fidelity Cas9 variants, and bioinformatics tools.

Off-target effects pose significant concerns for the safety and efficacy of genome editing treatments, impeding market demand. Unintended genetic changes can lead to harmful side effects, potentially introducing new mutations or exacerbating existing conditions. Regulatory scrutiny and public perception further hinder market growth. Regulators, like the FDA, require rigorous testing to ensure safety, which is time-consuming and costly. Public skepticism about the risks of off-target effects can also deter patients from seeking genome editing treatments. To address these challenges, researchers are developing new tools and techniques to enhance CRISPR precision and mitigate off-target effects, aiming to boost confidence and demand in the market.

What Questions Should You Ask before Buying a Market Research Report?

How is the genome editing technologies market evolving?

What is driving and restraining the genome editing technologies market?

How will each genome editing technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each genome editing technologies submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading genome editing technologies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the genome editing technologies projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of genome editing technologies projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the genome editing technologies market?

Where is the genome editing technologies market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the genome editing technologies market today, and over the next 10 years:

Our 311-page report provides 127 tables and 182 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the genome editing technologies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising genome editing technologies prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Technology

CRISPR

TALEN

ZFN

Meganucleases

Others

Application

Genetic Engineering

Cell Line Engineering

Animal Genetic Engineering

Plant Genetic Engineering

Others

Drug Discovery & Development

Diagnostic Applications

End-users

Biotechnology Companies

Pharmaceutical Companies

Academic & Government Research Institutes

Other End-users

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Genome Editing Technologies Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Agilent Technologies

Caribou Biosciences, Inc.

Cellectis

Cibus Inc.

CRISPR Therapeutics

Danaher Corporation

Editas Medicine

GenScript

Intellia Therapeutics Inc.

Lonza

Merck KGaA

Precision Biosciences

Recombinetics

Revvity

Sangamo Therapeutics

Takara Bio Inc.

Tecan Trading AG

Thermo Fisher Scientific Inc.

Overall world revenue for Genome Editing Technologies Market, 2024 to 2034 in terms of value the market will surpass US$6,300.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Genome Editing Technologies Market, 2024 to 2034 report help you?

In summary, our 310+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Genome Editing Technologies Market, 2024 to 2034, with forecasts for technology, application, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 22 key national markets - See forecasts for the Genome Editing Technologies Market, 2024 to 2034 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also includes forecast for the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 18 of the major companies involved in the Genome Editing Technologies Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Genome Editing Technologies Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Genome Editing Technologies Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Rising Number of Genomic Projects Coupled with the Government Funding
      • 3.2.1.2 Rising Adoption of Genome Editing Technologies
      • 3.2.1.3 Rising Burden of Chronic Diseases
      • 3.2.1.4 Increasing Applications of Genomics for Medicine, Agriculture, and Biotechnology
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Off-target Effects of CRISPR Technology
      • 3.2.2.2 High Cost of Genome Editing Technologies
      • 3.2.2.3 Regulatory Hurdles for Genome Editing Technology Application
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Rising Demand for Genome Editing Technology in Emerging Economies
      • 3.2.3.2 Strong Product Pipeline with Genome Editing Technology
      • 3.2.3.3 Collaboration and Partnerships among Genome Editing Technologies Companies
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat of Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Genome Editing Technologies Market Analysis by Technology

  • 4.1 Key Findings
  • 4.2 Technology Segment: Market Attractiveness Index
  • 4.3 Genome Editing Technologies Market Size Estimation and Forecast by Technology
  • 4.4 CRISPR
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 TALEN
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 ZFN
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)
  • 4.7 Meganucleases
    • 4.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 4.8 Others
    • 4.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.8.2 Market Share by Region, 2024 & 2034 (%)

5 Genome Editing Technologies Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Genome Editing Technologies Market Size Estimation and Forecast by Application
  • 5.4 Genetic Engineering
    • 5.4.1 Market Size Estimation and Forecast by Type
    • 5.4.2 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.3 Market Share by Region, 2024 & 2034 (%)
    • 5.4.4 Cell Line Engineering
      • 5.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.4.2 Market Share by Region, 2024 & 2034 (%)
    • 5.4.5 Animal Genetic Engineering
      • 5.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.5.2 Market Share by Region, 2024 & 2034 (%)
    • 5.4.6 Plant Genetic Engineering
      • 5.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.6.2 Market Share by Region, 2024 & 2034 (%)
    • 5.4.7 Others
      • 5.4.7.1 Market Size by Region, 2024-2034 (US$ Million)
      • 5.4.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Drug Discovery & Development
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Diagnostic Applications
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Genome Editing Technologies Market Analysis by End-users

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 Genome Editing Technologies Market Size Estimation and Forecast by End-users
  • 6.4 Biotechnology Companies
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Pharmaceutical Companies
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Academic & Government Research Institutes
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Other End-users
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)

7 Genome Editing Technologies Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America Genome Editing Technologies Market Analysis

  • 8.1 Key Findings
  • 8.2 North America Genome Editing Technologies Market Attractiveness Index
  • 8.3 North America Genome Editing Technologies Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 8.4 North America Genome Editing Technologies Market Size Estimation and Forecast by Country
  • 8.5 North America Genome Editing Technologies Market Size Estimation and Forecast by Technology
  • 8.6 North America Genome Editing Technologies Market Size Estimation and Forecast by Application
    • 8.6.1 North America Genome Editing Technologies Market Size Estimation and Forecast by Genetic Engineering
  • 8.7 North America Genome Editing Technologies Market Size Estimation and Forecast by End-users
  • 8.8 U.S. Genome Editing Technologies Market Analysis
  • 8.9 Canada Genome Editing Technologies Market Analysis

9 Europe Genome Editing Technologies Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe Genome Editing Technologies Market Attractiveness Index
  • 9.3 Europe Genome Editing Technologies Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 Europe Genome Editing Technologies Market Size Estimation and Forecast by Country
  • 9.5 Europe Genome Editing Technologies Market Size Estimation and Forecast by Technology
  • 9.6 Europe Genome Editing Technologies Market Size Estimation and Forecast by Application
    • 9.6.1 Europe Genome Editing Technologies Market Size Estimation and Forecast by Genetic Engineering
  • 9.7 Europe Genome Editing Technologies Market Size Estimation and Forecast by End-users
  • 9.8 Germany Genome Editing Technologies Market Analysis
  • 9.9 UK Genome Editing Technologies Market Analysis
  • 9.10 France Genome Editing Technologies Market Analysis
  • 9.11 Italy Genome Editing Technologies Market Analysis
  • 9.12 Spain Genome Editing Technologies Market Analysis
  • 9.13 Russia Genome Editing Technologies Market Analysis
  • 9.14 Rest of Europe Genome Editing Technologies Market Analysis

10 Asia Genome Editing Technologies Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Genome Editing Technologies Market Attractiveness Index
  • 10.3 Asia Genome Editing Technologies Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Asia Genome Editing Technologies Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific Genome Editing Technologies Market Size Estimation and Forecast by Technology
  • 10.6 Asia Pacific Genome Editing Technologies Market Size Estimation and Forecast by Application
    • 10.6.1 Asia Pacific Genome Editing Technologies Market Size Estimation and Forecast by Genetic Engineering
  • 10.7 Asia Pacific Genome Editing Technologies Market Size Estimation and Forecast by End-users
  • 10.8 Japan Genome Editing Technologies Market Analysis
  • 10.9 China Genome Editing Technologies Market Analysis
  • 10.10 India Genome Editing Technologies Market Analysis
  • 10.11 Australia Genome Editing Technologies Market Analysis
  • 10.12 South Korea Genome Editing Technologies Market Analysis
  • 10.13 Rest of Asia Genome Editing Technologies Market Analysis

11 Latin America Genome Editing Technologies Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America Genome Editing Technologies Market Attractiveness Index
  • 11.3 Latin America Genome Editing Technologies Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Latin America Genome Editing Technologies Market Size Estimation and Forecast by Country
  • 11.5 Latin America Genome Editing Technologies Market Size Estimation and Forecast by Technology
  • 11.6 Latin America Genome Editing Technologies Market Size Estimation and Forecast by Application
    • 11.6.1 Latin America Genome Editing Technologies Market Size Estimation and Forecast by Genetic Engineering
  • 11.7 Latin America Genome Editing Technologies Market Size Estimation and Forecast by End-users
  • 11.8 Brazil Genome Editing Technologies Market Analysis
  • 11.9 Mexico Genome Editing Technologies Market Analysis
  • 11.10 Argentina Genome Editing Technologies Market Analysis
  • 11.11 Rest of Latin America Genome Editing Technologies Market Analysis

12 MEA Genome Editing Technologies Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA Genome Editing Technologies Market Attractiveness Index
  • 12.3 MEA Genome Editing Technologies Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 MEA Genome Editing Technologies Market Size Estimation and Forecast by Country
  • 12.5 MEA Genome Editing Technologies Market Size Estimation and Forecast by Technology
  • 12.6 MEA Genome Editing Technologies Market Size Estimation and Forecast by Application
    • 12.6.1 MEA Genome Editing Technologies Market Size Estimation and Forecast by Genetic Engineering
  • 12.7 MEA Genome Editing Technologies Market Size Estimation and Forecast by End-users
  • 12.8 GCC Genome Editing Technologies Market Analysis
  • 12.9 South Africa Genome Editing Technologies Market Analysis
  • 12.10 Rest of MEA Genome Editing Technologies Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2023
  • 13.2 Strategic Outlook
  • 13.3 Thermo Fisher Scientific Inc.
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2018-2023
      • 13.3.3.2 R&D, 2018-2023
      • 13.3.3.3 Regional Market Shares, 2023
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Lonza
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 Net Revenue, 2018-2023
      • 13.4.3.2 R&D, 2018-2023
    • 13.4.4 Product Benchmarking
    • 13.4.5 Strategic Outlook
  • 13.5 CRISPR Therapeutics
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2018-2023
      • 13.5.3.2 R&D, 2018-2023
    • 13.5.4 Product Benchmarking
    • 13.5.5 Strategic Outlook
  • 13.6 Editas Medicine
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Financial Analysis
      • 13.6.3.1 Net Revenue, 2018-2023
      • 13.6.3.2 R&D, 2018-2023
    • 13.6.4 Product Benchmarking
    • 13.6.5 Strategic Outlook
  • 13.7 Revvity
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2018-2023
      • 13.7.3.2 R&D, 2018-2023
      • 13.7.3.3 Regional Market Shares, 2023
    • 13.7.4 Product Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 Agilent Technologies
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Financial Analysis
      • 13.8.3.1 Net Revenue, 2018-2023
      • 13.8.3.2 R&D, 2018-2023
      • 13.8.3.3 Regional Market Shares, 2023
    • 13.8.4 Product Benchmarking
    • 13.8.5 Strategic Outlook
  • 13.9 GenScript
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Financial Analysis
      • 13.9.3.1 Net Revenue, 2018-2023
      • 13.9.3.2 R&D, 2018-2023
    • 13.9.4 Product Benchmarking
    • 13.9.5 Strategic Outlook
  • 13.10 Merck KGaA
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2018-2023
      • 13.10.3.2 R&D, 2018-2023
      • 13.10.3.3 Regional Market Shares, 2023
    • 13.10.4 Product Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Sangamo Therapeutics
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2018-2023
      • 13.11.3.2 R&D, 2018-2023
    • 13.11.4 Product Benchmarking
    • 13.11.5 Strategic Outlook
  • 13.12 Precision Biosciences
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Financial Analysis
      • 13.12.3.1 Net Revenue, 2018-2023
      • 13.12.3.2 R&D, 2018-2023
    • 13.12.4 Product Benchmarking
    • 13.12.5 Strategic Outlook
  • 13.13 Tecan Trading AG
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Financial Analysis
      • 13.13.3.1 Net Revenue, 2018-2023
      • 13.13.3.2 R&D, 2018-2023
      • 13.13.3.3 Regional Market Shares, 2023
    • 13.13.4 Product Benchmarking
    • 13.13.5 Strategic Outlook
  • 13.14 Takara Bio Inc.
    • 13.14.1 Company Snapshot
    • 13.14.2 Company Overview
    • 13.14.3 Financial Analysis
      • 13.14.3.1 Net Revenue, 2018-2023
    • 13.14.4 Product Benchmarking
    • 13.14.5 Strategic Outlook
  • 13.15 Danaher Corporation
    • 13.15.1 Company Snapshot
    • 13.15.2 Company Overview
    • 13.15.3 Financial Analysis
      • 13.15.3.1 Net Revenue, 2018-2023
      • 13.15.3.2 R&D, 2018-2023
      • 13.15.3.3 Regional Market Shares, 2023
    • 13.15.4 Product Benchmarking
    • 13.15.5 Strategic Outlook
  • 13.16 Recombinetics
    • 13.16.1 Company Snapshot
    • 13.16.2 Company Overview
    • 13.16.3 Product Benchmarking
  • 13.17 Intellia Therapeutics Inc.
    • 13.17.1 Company Snapshot
    • 13.17.2 Company Overview
    • 13.17.3 Financial Analysis
      • 13.17.3.1 Net Revenue, 2018-2023
      • 13.17.3.2 R&D, 2018-2023
    • 13.17.4 Product Benchmarking
    • 13.17.5 Strategic Outlook
  • 13.18 Cellectis
    • 13.18.1 Company Snapshot
    • 13.18.2 Company Overview
    • 13.18.3 Financial Analysis
      • 13.18.3.1 Net Revenue, 2018-2023
      • 13.18.3.2 R&D, 2018-2023
      • 13.18.3.3 Regional Market Shares, 2023
    • 13.18.4 Product Benchmarking
    • 13.18.5 Strategic Outlook
  • 13.19 Cibus Inc.
    • 13.19.1 Company Snapshot
    • 13.19.2 Company Overview
    • 13.19.3 Financial Analysis
      • 13.19.3.1 Net Revenue, 2018-2023
      • 13.19.3.2 R&D, 2018-2023
    • 13.19.4 Product Benchmarking
    • 13.19.5 Strategic Outlook
  • 13.20 Caribou Biosciences, Inc.
    • 13.20.1 Company Snapshot
    • 13.20.2 Company Overview
    • 13.20.3 Financial Analysis
      • 13.20.3.1 Net Revenue, 2019-2023
      • 13.20.3.2 R&D, 2019-2023
      • 13.20.3.3 Regional Market Shares, 2023
    • 13.20.4 Product Benchmarking

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제